Moderna, Inc. (NASDAQ:MRNA) Stock Holdings Increased by Himension Capital Singapore PTE. LTD.

Himension Capital Singapore PTE. LTD. boosted its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 201.0% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 31,598 shares of the company’s stock after purchasing an additional 21,102 shares during the period. Himension Capital Singapore PTE. LTD.’s holdings in Moderna were worth $1,314,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB increased its stake in shares of Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after acquiring an additional 587 shares during the last quarter. Compass Planning Associates Inc acquired a new position in Moderna in the 4th quarter worth about $37,000. Venturi Wealth Management LLC raised its stake in shares of Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after purchasing an additional 664 shares in the last quarter. Crowley Wealth Management Inc. bought a new stake in shares of Moderna in the 4th quarter valued at approximately $41,000. Finally, MassMutual Private Wealth & Trust FSB raised its position in Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after acquiring an additional 389 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on MRNA shares. Argus lowered shares of Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Citigroup assumed coverage on shares of Moderna in a research report on Thursday, March 13th. They set a “neutral” rating and a $40.00 target price on the stock. Barclays cut Moderna from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $111.00 to $45.00 in a research report on Tuesday, February 18th. Leerink Partners lowered their price objective on Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a report on Thursday, January 16th. Finally, Morgan Stanley reduced their target price on Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a report on Wednesday, January 15th. Four analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $59.00.

Moderna Trading Down 2.4 %

Shares of NASDAQ MRNA opened at $25.11 on Friday. Moderna, Inc. has a one year low of $23.76 and a one year high of $170.47. The business has a fifty day simple moving average of $33.55 and a 200 day simple moving average of $42.80. The firm has a market capitalization of $9.71 billion, a price-to-earnings ratio of -2.71 and a beta of 2.23.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.